GlassScriptPhysician profile
Heather Gladue
NPI 1790949642
$168,225.12
in general payments reported to CMS, 2019-2025
35 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,096 · 2020: $6,080 · 2021: $11K · 2022: $31K · 2023: $50K · 2024: $41K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Consulting Fee: $10K · Food and Beverage: $9,747 · Travel and Lodging: $6,602 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,655.72 |
| Consulting Fee | $10,300.00 |
| Food and Beverage | $9,747.30 |
| Travel and Lodging | $6,601.73 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $57,222.14 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $54,712.33 | 2019-2025 | Benlysta |
| Abbvie INC. | $24,021.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,679.28 | 2023-2024 | Ofev, Cyltezo |
| Sobi, INC | $2,204.03 | 2025 | |
| Amgen INC. | $2,145.12 | 2019-2025 | Enbrel, Evenity, Otezla |
| Fresenius Kabi USA, LLC | $1,361.31 | 2023-2024 | Idacio |
| Novartis Pharmaceuticals Corporation | $1,053.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $960.38 | 2019-2025 | Orencia |
| Ucb, INC. | $859.85 | 2019-2025 | Bimzelx, Cimzia, Fintepla |
| Lilly USA, LLC | $808.82 | 2019-2024 | Taltz, Olumiant |
| Janssen Biotech, INC. | $780.64 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $723.69 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $525.00 | 2019 | |
| Radius Health, INC. | $372.34 | 2019-2025 | Tymlos |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $325.97 | 2019-2025 | Actemra, Gazyva, Rituxan |
| Aurinia Pharma U.S., INC. | $262.39 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $258.60 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $167.31 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $129.60 | 2023-2025 | Acthar |
| Sandoz INC. | $118.10 | 2024-2025 | Hyrimoz, Jubbonti |
| Ani Pharmaceuticals, INC. | $83.79 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $79.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $74.77 | 2019 | |
| Scilex Pharmaceuticals INC. | $45.09 | 2024-2025 | |
| Medexus Pharma, INC. | $45.03 | 2019 | |
| Merck Sharp & Dohme LLC | $38.01 | 2019-2021 | |
| Tonix Medicines, INC. | $33.63 | 2025 | Tonmya |
| Organon LLC | $33.02 | 2021-2022 | |
| Pacira Therapeutics, INC. | $22.79 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.39 | 2019 | |
| Antares Pharma, INC. | $16.74 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $15.99 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $15.34 | 2023 | |
| Hikma Pharmaceuticals USA | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gladue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.